Filter
99
Featured
Recommendations
13
New Publications
10
Language
Document type
Guidelines
34
No document type
34
Studies & Reports
9
Training Material
7
Fact sheets
7
Manuals
3
Resource Platforms
3
Strategic & Response Plan
2
Countries / Regions
South Africa
6
Malawi
3
Uganda
2
Latin America and the Carribbean
2
Western and Central Europe
2
Ethiopia
1
Kenya
1
Cambodia
1
Ukraine
1
El Salvador
1
Africa
1
Laos
1
Vietnam
1
Authors & Publishers
Publication Years
Category
Countries
16
Clinical Guidelines
14
Capacity Building
3
Pharmacy & Technologies
1
WHO’s antiretroviral treatment (ART) clinic-based acquired drug resistance survey method yields robust estimates of HIV viral suppression and acquired HIV drug resistance in adults, children and adolescents taking both dolutegravir and non-dolutegravir based regimens.
Results are used to inform A
...
- A Skills Building Program for Clinicians and Non-Clinicians. Adherence guidelines- slide deck- training course for health providers
Int. J. Environ. Res. Public Health 2021, 18(5), 2477; https://doi.org/10.3390/ijerph18052477
Program Considerations
HIV-1 drug resistance (HIVDR) genotyping is an essential component of the WHO global HIVDR surveillance strategy. Plasma “gold standard” specimen type for HIVDR genotyping, but its use may not be feasible in rural, remote areas in low- and middle-income countries, since preparing and storing it
...
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i
...
The aim of the operational framework is to ensure 1) accurate collection, handling, shipment and storage of specimens collected in countries implementing HIV drug resistance surveillance; and 2) the availability of quality-assured HIV genotyping laboratory services producing comparable and reliable
...
En la presente publicación se formulan orientaciones sobre la respuesta de salud pública a la farmacorresistencia del VIH (FRVIH) a inhibidores no nucleosídicos de la retrotranscriptasa (INNRT), previa al tratamiento, en personas con exposición previa a los fármacos antirretrovirales (ARV) o si
...
